Mechanism of lentiviral inhibition by Mx2

Information

  • Research Project
  • 9021538
  • ApplicationId
    9021538
  • Core Project Number
    F32AI116263
  • Full Project Number
    5F32AI116263-02
  • Serial Number
    116263
  • FOA Number
    PA-14-149
  • Sub Project Id
  • Project Start Date
    2/13/2015 - 9 years ago
  • Project End Date
    2/12/2018 - 6 years ago
  • Program Officer Name
    KUO, LILLIAN S.
  • Budget Start Date
    2/13/2016 - 8 years ago
  • Budget End Date
    2/12/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    02
  • Suffix
  • Award Notice Date
    1/12/2016 - 8 years ago

Mechanism of lentiviral inhibition by Mx2

? DESCRIPTION (provided by applicant): HIV-1 encounters many obstacles to viral replication in the host cell, which is armed with an intrinsic immune system of antiviral factors with direct antiviral activity, including APOBEC3G, TRIM5alpha, Tetherin, SAMHD1, and Mx2. Our understanding of the mechanism by which these factors inhibit retroviral replication, and how they are evaded by certain viruses has accrued significantly, but is far from complete. Such knowledge could greatly aid the development of new animal models of human disease and novel therapeutic intervention. The goal of this project is to investigate the mechanistic basis fo inhibition of HIV-1 infection by the newly identified factor, Mx2. The first aim of this project is to identify the cellular requirements for the localization and antviral activity of Mx2. It is unknown how Mx2 interacts with the nuclear pore complex, how it may be involved in regulation of nuclear import, or how the localization of Mx2 at the nuclear pore drives its antiviral activity. Both targeted and non-biased approaches will be employed to precisely identify cellular factors important for the antiviral activity of Mx2. The second aim is to determie the nature of the interaction between Mx2 and the HIV-1 capsid. It is known that the capsid is the determinant of sensitivity or resistance to inhibition by Mx2, but the mechanistic basis for this interaction remains unknown. Independent but complementary biochemical and genetic approaches will be utilized to define the precise interface that determines the antiviral specificiy of Mx2. The knowledge gained by this project will provide an enhanced understanding of how Mx2 inhibits the early stages of HIV-1 infection and can be utilized to develop new, targeted anti-retroviral therapies.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    F32
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    59970
  • Indirect Cost Amount
  • Total Cost
    59970
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:59970\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AARON DIAMOND AIDS RESEARCH CENTER
  • Organization Department
  • Organization DUNS
    786658872
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100169102
  • Organization District
    UNITED STATES